Mike Romanos is a biopharma executive with 30 years’ experience in the industry, covering drug discovery and associated technologies across therapeutic areas, phases and modalities (NCE, biologics, gene therapy, and vaccines).
Mike spent ten years in global management roles with GlaxoSmithKline, where he made a lasting impact on the company’s R&D strategy and pipeline, including building several international organisations that translated cutting edge science into target and biomarker discovery, and candidate discovery in biologics and NCEs. These groups made key contributions in establishing the company’s antibody pipeline and in building target class-based discovery capability that delivered novel targets and candidates (e.g. in ion channels and GPCRs).
After leaving GSK he started Crescendo Biologics in 2009, where he was CEO for six years, building a leading antibody fragment platform (HumabodyTM), a fully integrated discovery capability and a differentiated product pipeline comprising Humabody Drug Conjugates, novel multivalent immune checkpoint inhibitors and a topical anti-IL17 Humabody for psoriasis.
Since his first industry role in Wellcome Biotech, Mike has led groups in antiviral research, gene therapy, novel vaccine development and recombinant protein production, and has been highly active in shaping IP strategy and in gaining and defending valuable patents. Prior to his career in industry Mike undertook academic research in influenza virus in the MRC’s National Institute for Medical Research and in recombinant yeast biotechnology at the University of Leicester.
Mike holds a degree in Natural Sciences from Cambridge University and a PhD in Molecular Virology from Imperial College, London. He is a Fellow of the Royal Society of Biology, a Member of the Institute of Directors, a Venture Partner for Rainbow Seed Fund, Translator in Residence at Imperial College and a panel member of the MRC’s DPFS committee for public funding of translational research.Back to our trustees